Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.11
+$0.05 · +4.72%
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
Previous close
$1.11
+$0.05 · +4.72%
Regular session · ET · Market data may be delayed.
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
Day range
Current $1.11
52-week range
Current $1.11
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
43
Fair Value
Sentiment
55
Mixed
Risk
76
High Risk
Momentum
18
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
Day range
Current $1.11
52-week range
Current $1.11
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6K USD | 11K USD | 9K USD | 88.6K USD | 87.75K USD |
| Cost of goods sold | 2.19K USD | 4.4K USD | 3.6K USD | 28.49K USD | 47.95K USD |
| Gross profit | 3.81K USD | 6.6K USD | 5.4K USD | 60.11K USD | 39.81K USD |
| Research and development | 2.26M USD | 2.4M USD | 1.97M USD | 6.27M USD | 109.18K USD |
| Selling, general, and administrative | 3.76M USD | 3.24M USD | 3.56M USD | 3.94M USD | 2.96M USD |
| Operating expenses | 6.15M USD | 5.75M USD | 5.63M USD | 10.3M USD | 3.17M USD |
| Interest income | 147.81K USD | 250.38K USD | 333.56K USD | 100.33K USD | — |
| Interest expense | — | — | — | — | 4.28M USD |
| Depreciation and amortization | 123.33K USD | 110.45K USD | 94.58K USD | 92.08K USD | 92.08K USD |
| Operating income | −6.14M USD | −5.74M USD | −5.62M USD | −10.24M USD | −3.13M USD |
| Net income | −6M USD | −5.49M USD | −5.29M USD | −10.14M USD | 19.21M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 12, 2023 | 1:10 | — | — |
Stock split | Nov 10, 2021 | 1:500 | — | — |
Stock split | Feb 3, 2020 | 1:150 | — | — |
Effective Jun 12, 2023
1:10
Effective Nov 10, 2021
1:500
Effective Feb 3, 2020
1:150
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
